A Phase 2a, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of MK-7264 on Acute Cough in Participants With Induced Viral Upper Respiratory Tract Infection
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
Price : $35 *
At a glance
- Drugs Gefapixant (Primary)
- Indications Cough
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Feb 2019 Status changed from recruiting to discontinued.
- 02 Nov 2018 Planned End Date changed from 10 Jun 2019 to 21 Jun 2019.
- 02 Nov 2018 Planned primary completion date changed from 10 Jun 2019 to 3 Jun 2019.